The U.S. digital therapeutics market is projected to reach $21.46 billion by 2030, growing at a CAGR of 33.8% from 2023 to 2030.
Share: email Subscribe
Weekly Top Stories Tue, 20 Jun 2023
We have 30 articles this week, # Coherus Expands Portfolio with $65M Acquisition of Surface Oncology # Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio. # Merck Completes Acquisition of Prometheus Biosciences, Inc.# Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited # Apixio and ClaimLogiq Merge to Minimize Reimbursement Inaccuracies.
Editor's Choice
1. 
 U.S. Digital Therapeutics Market to Reach $21.46B by 2030
2. 
 HandSport Surgery Institute Launches Virtual Practice in Metaverse.
3. 
 Value-Based Care Versus Fee-for-Service: Understanding the Key Differences in Healthcare Models
4. 
 Cala Launches FDA-Cleared Wearable Device for Tremor Relief
5. 
 New AI model for screening gingivitis developed in Hong Kong
Top 10 M&A Transactions
6. 
 Coherus Expands Portfolio with $65M Acquisition of Surface Oncology
7. 
 Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
8. 
 Merck Completes Acquisition of Prometheus Biosciences, Inc.
9. 
 Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 Billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited
10. 
 Apixio and ClaimLogiq Merge to Minimize Reimbursement Inaccuracies
11. 
 RK Pharma Completes Acquisition of VGYAAN Pharmaceuticals.
12. 
 MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
13. 
 Validic Acquires Connected Health Platform Trapollo
14. 
 Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
15. 
 ProciseDx Announces Acquisition by Biosynex S.A. to Transform Biologics Therapeutic Drug Monitoring in the US.
Top 4 Venture Funding
16. 
 Hybrid Behavioral Healthcare Company Octave Scores $52M
17. 
 Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
18. 
 Inaccurate Drug Discount Requests Reach Nearly $1B.
19. 
 Wound Company Launches With $4.25M to Fix Inequities in Wound Care
Top 4 Partnerships Announcements
20. 
 Walgreens and Freenome Partner to Increase Diversity in Research
21. 
 Emory Healthcare and DispatchHealth Partner to Offer In-Home Care to Patients in Metro-Atlanta
22. 
 Pear Suite Partners with OutCare Health to Expand LGBTQ+ Care.
23. 
 Walmart, Simple HealthKit Partner to Offer At-Home Testing.
Read More Corporate Development and M&A Activity
Get Featured: Send us your article or blog and we will feature it on our publication, reach over thousands of executives. Click Here.
Editor: Ed Francis

Ed has more than 25 years of management consulting experience and currently is the Global Managing Partner for Infosys Consulting Health and Life Sciences business guiding some of the industry's most prominent health and life sciences organizations through complex transformations.

If you need help with your complex transformation whether it be M&A, digital, or strategic cost reduction or need to bring more innovation into your business strategy Ed can be contacted at Edward.Francis@infosys.com and +1-847-910-6073

Or connect with him at

OTHER ADVISORIES

Health Plan Hospital IT
IT GovHealth
Retail POP Health
Ageing Life Sciences

Advertise with us

We Reach Half Million Decision Makers in:
Healthcare · IT · Retail · Industrial
Advertise with us and reach the right audience.
advertise@distilnfo.com

Contact Us

5760 Legacy Dr, B3-405,
Plano TX 75024
+1 469-270-3311

DistilINFO Publications

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you - saving time and keeping you up to date on your interest areas.

You are receiving this newsletter because you are subscribed to one or more DistilINFO Publications Newsletter/s. If you feel this email was sent by mistake or you want to opt out, you can unsubscribe.

View in browser | Advertise | Contact Us